AEterna Zentaris (TSX:AEZS) Operating Cash Flow per Share

: C$-4.75 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

AEterna Zentaris's operating cash flow per share for the three months ended in Dec. 2023 was C$-1.49. AEterna Zentaris's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-4.75.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -13.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for AEterna Zentaris's Operating Cash Flow per Share or its related term are showing as below:

TSX:AEZS' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -125.1 Med: 32.7 Max: 68
Current: -13.7

During the past 13 years, AEterna Zentaris's highest 3-Year average Operating Cash Flow per Share Growth Rate was 68.00% per year. The lowest was -125.10% per year. And the median was 32.70% per year.

TSX:AEZS's 3-Year OCF Growth Rate is ranked worse than
69.23% of 1235 companies
in the Biotechnology industry
Industry Median: 3.2 vs TSX:AEZS: -13.70

AEterna Zentaris Operating Cash Flow per Share Historical Data

The historical data trend for AEterna Zentaris's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-20.18

-3.22

-2.39

-3.83

-4.73

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.96	-1.14	-1.18	-0.94	-1.49

Competitive Comparison

For the Biotechnology subindustry, AEterna Zentaris's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Price-to-Operating-Cash-Flow falls into.

AEterna Zentaris Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

AEterna Zentaris's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-22.966	/	4.856
	=	-4.73

AEterna Zentaris's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-7.218	/	4.858
	=	-1.49

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.75

AEterna Zentaris Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.